HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.

Recent Events

• HepQuant attended the AASLD Liver Meeting in San Francisco, Nov. 9 – 13th. The event is typically attended by more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world.   (More info.) The company presented 2 posters:

“Defining and Monitoring Liver Disease in Chronic Hepatitis C:  A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT test with Ishak Fibrosis (IFS) from Liver Biopsy.” Everson GT, Helmke SM.  Hepatology 2018;68:910A. Annotation: This study suggests that DSI may be more sensitive than IFS in measuring serial changes in disease in patients with chronic hepatitis C.

“Defining Disease Severity and Measuring Progression in Primary Sclerosing Cholangitis (PSC):  A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT Test with Serum Alkaline Phosphatase (Alk Phos).”  Helmke SM, Everson GT. Hepatology 2018;1087A. Annotation: This study suggests that DSI may be more sensitive than Alk Phos in measuring serial changes in disease in patients with PSC.

Recently Attended

HepQuant’s Chief Business Development Officer Brad Everson and Chief Scientific Officer Dr. Steve Helmke recently attended the 3rd edition of the International Workshop on NASH Biomarkers in Washington, DC.